文献速递淋巴瘤

单细胞多组学解析套细胞淋巴瘤对Pirtobrutinib的耐药机制

Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics.
PubMed 文献 · Am J Hematol · 2026-04-17

该研究对接受Pirtobrutinib(PBN)治疗的套细胞淋巴瘤(MCL)患者纵向样本进行单细胞多组学分析(scRNA-seq、scATAC-seq、scDNA-seq),揭示耐药可通过遗传途径(如1q、2p、8q拷贝数增益)或非遗传途径(转录与表观遗传重塑)发生。整合分析提示 cohesin 复合体核心组分RAD21和SMC3下调可能使细胞对PBN重新敏感,耐药样本中富集的干细胞样恶性B细胞群表现出代谢重编程和上皮-间质转化特征。

要点

  • PBN耐药存在遗传与非遗传双重机制,呈异质性多层调控。
  • RAD21和SMC3等染色质调控因子下调可能逆转PBN耐药。
  • 耐药样本富集干细胞样恶性B细胞,伴代谢重编程与EMT特征。

核心结论

  • PBN耐药机制具有异质性和多层性,涉及遗传与非遗传途径。
  • 染色质调控因子RAD21和SMC3可能成为克服PBN耐药的治疗靶点。

研究设计与样本

  • 对纵向MCL患者样本进行整合单细胞多组学分析(scRNA-seq、scATAC-seq和scDNA-seq)。

主要发现

  • 部分患者耐药涉及1q、2p和8q等拷贝数增益,伴随转录组重编程和表观遗传改变。
  • 另一些患者耐药通过转录和表观遗传重塑驱动的非遗传机制发生。
  • 耐药样本中富集干细胞样恶性B细胞群,表现代谢重编程和上皮-间质转化特征。
  • 整合scATAC-seq与scRNA-seq进行基因调控网络推断和计算机扰动分析,提示RAD21和SMC3下调可能使细胞对PBN重新敏感。

临床怎么用

  • PBN耐药机制异质,临床需考虑遗传与非遗传双重因素。
  • 染色质调控因子RAD21和SMC3或可作为逆转PBN耐药的潜在靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pirtobrutinib (PBN), a non-covalent BTK inhibitor, has been approved by the FDA for relapsed/refractory mantle cell lymphoma (MCL); however, resistance to PBN has been observed. To dissect the molecular dynamics driving PBN resistance, we performed integrative single-cell multi-omic profiling (scRNA-seq, scATAC-seq, and scDNA-seq) on longitudinal MCL patient samples. Our analyses revealed both genetic and non-genetic routes of resistance: In some patients, resistance involves sequential copy number gains (e.g., 1q, 2p, and 8q) accompanied by transcriptomic reprogramming and epigenetic alterations, whereas in others, resistance occurs through non-genetic mechanisms driven by transcriptional and epigenetic remodeling. Integration of scATAC-seq and scRNA-seq enabled gene regulatory network inference and in silico perturbation analysis, highlighting RAD21 and SMC3, core components of the cohesin complex, as chromatin regulators whose downregulation may re-sensitize cells to PBN. A stem-like malignant B cell population enriched in resistant samples exhibited features of metabolic reprogramming and epithelial-mesenchymal transition. Together, our findings highlight heterogeneous, multi-layered mechanisms of PBN resistance and suggest chromatin regulators as potential therapeutic targets to overcome PBN resistance in MCL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Yan F, Liu Y, Lee HH, et al. Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics. Am J Hematol. 2026. PMID: 41998849. doi:10.1002/ajh.70304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。